nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbidopa—Extravasation—Methotrexate—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Carbidopa—Weight increased—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Carbidopa—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Carbidopa—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Carbidopa—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Carbidopa—Myocardial infarction—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Carbidopa—Feeling abnormal—Teniposide—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Carbidopa—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Carbidopa—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Carbidopa—Nausea—Mechlorethamine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Carbidopa—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Carbidopa—Alopecia—Bleomycin—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Carbidopa—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Carbidopa—Haemoglobin—Carmustine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Carbidopa—Urticaria—Teniposide—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Carbidopa—Haemorrhage—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Carbidopa—Body temperature increased—Teniposide—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Carbidopa—Abdominal pain—Teniposide—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Carbidopa—Paraesthesia—Fludarabine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Carbidopa—Hallucination—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Carbidopa—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Carbidopa—Dyspnoea—Fludarabine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Carbidopa—Dyspepsia—Fludarabine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Carbidopa—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Carbidopa—Decreased appetite—Fludarabine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Carbidopa—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Carbidopa—Fatigue—Fludarabine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Carbidopa—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Carbidopa—Hallucination—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Carbidopa—Constipation—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Carbidopa—Pain—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Carbidopa—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Carbidopa—Urethral disorder—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Carbidopa—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Carbidopa—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Carbidopa—Hypersensitivity—Teniposide—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Carbidopa—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Carbidopa—Flushing—Carmustine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Carbidopa—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Carbidopa—Anaemia—Bleomycin—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Carbidopa—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Carbidopa—Asthenia—Teniposide—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Carbidopa—Malaise—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Carbidopa—Pruritus—Teniposide—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Carbidopa—Leukopenia—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Carbidopa—Alopecia—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Carbidopa—Body temperature increased—Fludarabine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Carbidopa—Mental disorder—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Carbidopa—Cough—Bleomycin—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Carbidopa—Diarrhoea—Teniposide—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Carbidopa—Chest pain—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Carbidopa—Alopecia—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Carbidopa—Back pain—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Carbidopa—Discomfort—Bleomycin—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Carbidopa—Mental disorder—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Carbidopa—Alopecia—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Carbidopa—Confusional state—Bleomycin—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Carbidopa—Vision blurred—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Carbidopa—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Carbidopa—Tremor—Carmustine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Carbidopa—Oedema—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Carbidopa—Infection—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Carbidopa—Anaemia—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Carbidopa—Back pain—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Carbidopa—Vomiting—Teniposide—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Carbidopa—Agitation—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Carbidopa—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Carbidopa—Asthenia—Fludarabine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Carbidopa—Rash—Teniposide—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Carbidopa—Dermatitis—Teniposide—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Carbidopa—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Carbidopa—Headache—Teniposide—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Carbidopa—Pruritus—Fludarabine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Carbidopa—Back pain—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Carbidopa—Leukopenia—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Carbidopa—Anorexia—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Carbidopa—Anaemia—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Carbidopa—Agitation—Vincristine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Carbidopa—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Carbidopa—Hypotension—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Carbidopa—Diarrhoea—Fludarabine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Carbidopa—Convulsion—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Carbidopa—Hypertension—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Carbidopa—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Carbidopa—Nausea—Teniposide—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Carbidopa—Anaemia—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Carbidopa—Leukopenia—Vincristine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Carbidopa—Chest pain—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Carbidopa—Anxiety—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Carbidopa—Paraesthesia—Bleomycin—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Carbidopa—Malaise—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Carbidopa—Dyspnoea—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Carbidopa—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Carbidopa—Convulsion—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Carbidopa—Hypertension—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Carbidopa—Confusional state—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Carbidopa—Oedema—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Carbidopa—Decreased appetite—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Carbidopa—Cough—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Carbidopa—Infection—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Carbidopa—Vomiting—Fludarabine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Carbidopa—Convulsion—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Carbidopa—Rash—Fludarabine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Carbidopa—Dermatitis—Fludarabine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Carbidopa—Hypertension—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Carbidopa—Pain—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Carbidopa—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Carbidopa—Headache—Fludarabine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Carbidopa—Chest pain—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Carbidopa—Anxiety—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Carbidopa—Discomfort—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Carbidopa—Oedema—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Carbidopa—Anorexia—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Carbidopa—Infection—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Carbidopa—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Carbidopa—Confusional state—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Carbidopa—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Carbidopa—Hypotension—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Carbidopa—Oedema—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Carbidopa—Nausea—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Carbidopa—Infection—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Carbidopa—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Carbidopa—Shock—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Carbidopa—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Carbidopa—Urticaria—Bleomycin—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Carbidopa—Anorexia—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Carbidopa—Body temperature increased—Bleomycin—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Carbidopa—Insomnia—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Carbidopa—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Carbidopa—Paraesthesia—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Carbidopa—Hypotension—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Carbidopa—Dyspnoea—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Carbidopa—Somnolence—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Carbidopa—Anorexia—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Carbidopa—Ataxia—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Carbidopa—Decreased appetite—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Carbidopa—Hypotension—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Carbidopa—Insomnia—Vincristine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Carbidopa—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Carbidopa—Paraesthesia—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Carbidopa—Pain—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Carbidopa—Constipation—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Carbidopa—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Carbidopa—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Carbidopa—Decreased appetite—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Carbidopa—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Carbidopa—Somnolence—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Carbidopa—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Carbidopa—Feeling abnormal—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Carbidopa—Fatigue—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Carbidopa—Asthenia—Bleomycin—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Carbidopa—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Carbidopa—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Carbidopa—Pain—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Carbidopa—Constipation—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Carbidopa—Pruritus—Bleomycin—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Carbidopa—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Carbidopa—Fatigue—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Carbidopa—Pain—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Carbidopa—Constipation—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Carbidopa—Abdominal pain—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Carbidopa—Body temperature increased—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Carbidopa—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Carbidopa—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Carbidopa—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Carbidopa—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Carbidopa—Body temperature increased—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Carbidopa—Abdominal pain—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Carbidopa—Urticaria—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Carbidopa—Hypersensitivity—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Carbidopa—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Carbidopa—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Carbidopa—Vomiting—Bleomycin—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Carbidopa—Depression—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Carbidopa—Rash—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Carbidopa—Dermatitis—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Carbidopa—Asthenia—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Carbidopa—Hypersensitivity—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Carbidopa—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Carbidopa—Asthenia—Vincristine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Carbidopa—Diarrhoea—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Carbidopa—Nausea—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Carbidopa—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Carbidopa—Asthenia—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Carbidopa—Dizziness—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Carbidopa—Haemoglobin—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Carbidopa—Diarrhoea—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Carbidopa—Haemorrhage—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Carbidopa—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Carbidopa—Urethral disorder—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Carbidopa—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Carbidopa—Vomiting—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Carbidopa—Dizziness—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Carbidopa—Rash—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Carbidopa—Dermatitis—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Carbidopa—Headache—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Carbidopa—Vomiting—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Carbidopa—Rash—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Carbidopa—Dermatitis—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Carbidopa—Headache—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Carbidopa—Nausea—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Carbidopa—Vomiting—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Carbidopa—Rash—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Carbidopa—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Carbidopa—Headache—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Carbidopa—Alopecia—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Carbidopa—Mental disorder—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Carbidopa—Nausea—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Carbidopa—Dysgeusia—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Carbidopa—Nausea—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Carbidopa—Back pain—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Carbidopa—Vision blurred—Methotrexate—lymphatic system cancer	0.000984	0.000984	CcSEcCtD
Carbidopa—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Carbidopa—Anaemia—Methotrexate—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Carbidopa—Malaise—Methotrexate—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Carbidopa—Leukopenia—Methotrexate—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Carbidopa—Cough—Methotrexate—lymphatic system cancer	0.000912	0.000912	CcSEcCtD
Carbidopa—Convulsion—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Carbidopa—Chest pain—Methotrexate—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Carbidopa—Discomfort—Methotrexate—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Carbidopa—Confusional state—Methotrexate—lymphatic system cancer	0.00086	0.00086	CcSEcCtD
Carbidopa—Infection—Methotrexate—lymphatic system cancer	0.000847	0.000847	CcSEcCtD
Carbidopa—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Carbidopa—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Carbidopa—Anorexia—Methotrexate—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Carbidopa—Hypotension—Methotrexate—lymphatic system cancer	0.000797	0.000797	CcSEcCtD
Carbidopa—Insomnia—Methotrexate—lymphatic system cancer	0.000771	0.000771	CcSEcCtD
Carbidopa—Paraesthesia—Methotrexate—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Carbidopa—Dyspnoea—Methotrexate—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Carbidopa—Somnolence—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Carbidopa—Dyspepsia—Methotrexate—lymphatic system cancer	0.00075	0.00075	CcSEcCtD
Carbidopa—Decreased appetite—Methotrexate—lymphatic system cancer	0.000741	0.000741	CcSEcCtD
Carbidopa—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Carbidopa—Fatigue—Methotrexate—lymphatic system cancer	0.000735	0.000735	CcSEcCtD
Carbidopa—Pain—Methotrexate—lymphatic system cancer	0.000729	0.000729	CcSEcCtD
Carbidopa—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000703	0.000703	CcSEcCtD
Carbidopa—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000697	0.000697	CcSEcCtD
Carbidopa—Urticaria—Methotrexate—lymphatic system cancer	0.000677	0.000677	CcSEcCtD
Carbidopa—Abdominal pain—Methotrexate—lymphatic system cancer	0.000674	0.000674	CcSEcCtD
Carbidopa—Body temperature increased—Methotrexate—lymphatic system cancer	0.000674	0.000674	CcSEcCtD
Carbidopa—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000628	0.000628	CcSEcCtD
Carbidopa—Asthenia—Methotrexate—lymphatic system cancer	0.000612	0.000612	CcSEcCtD
Carbidopa—Pruritus—Methotrexate—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Carbidopa—Diarrhoea—Methotrexate—lymphatic system cancer	0.000583	0.000583	CcSEcCtD
Carbidopa—Dizziness—Methotrexate—lymphatic system cancer	0.000564	0.000564	CcSEcCtD
Carbidopa—Vomiting—Methotrexate—lymphatic system cancer	0.000542	0.000542	CcSEcCtD
Carbidopa—Rash—Methotrexate—lymphatic system cancer	0.000538	0.000538	CcSEcCtD
Carbidopa—Dermatitis—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Carbidopa—Headache—Methotrexate—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Carbidopa—Nausea—Methotrexate—lymphatic system cancer	0.000506	0.000506	CcSEcCtD
